Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Capricor Completes BLA for Deramiocel for Duchenne Cardiomyopathy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • المؤلفون: Myshko, Denise
  • المصدر:
    Formulary Watch. 1/3/2025, p1-1. 1p.
  • معلومة اضافية
    • نبذة مختصرة :
      The article focuses on the Capricor Therapeutics Inc.' completion of a biologics license application (BLA) for deramiocel, a cell therapy for treating Duchenne muscular dystrophy cardiomyopathy. Topics include deramiocel's potential as the first approved therapy for this condition; the regenerative properties of its cardiosphere-derived cells; and clinical trial data demonstrating cardiac and functional benefits.